Cargando…

Efficacy and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis patients: a systematic review and meta-analysis of randomised controlled trials

OBJECTIVES: Idiopathic pulmonary fibrosis (IPF) has been defined as a distinctive type of chronic fibrotic disease, characterised by a progressive decline in lung function and a common histological pattern of interstitial pneumonia. To analyse the efficacy and safety of pirfenidone in the treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Wenjuan, Qiu, Lingxiao, Wu, Jizhen, Liu, Xueya, Zhang, Guojun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Respiratory Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720994/ https://www.ncbi.nlm.nih.gov/pubmed/34972762 http://dx.doi.org/10.1136/bmjopen-2021-050004

Ejemplares similares

Contribution of Adiponectin/Carnitine Palmityl Transferase 1A-Mediated Fatty Acid Metabolism during the Development of Idiopathic Pulmonary Fibrosis
por: Wu, Wenjuan, et al.
Publicado: (2022)

Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis
por: Takeda, Yoshito, et al.
Publicado: (2014)

Efficacy and safety of nintedanib in Japanese patients with early-stage idiopathic pulmonary fibrosis: a study protocol for an observational study
por: Sakamoto, Noriho, et al.
Publicado: (2021)

Systematic review and meta-analysis of clinical significance of autoantibodies for idiopathic pulmonary fibrosis
por: Kamiya, Hiroyuki, et al.
Publicado: (2019)

Systematic review and network meta-analysis of approved medicines for the treatment of idiopathic pulmonary fibrosis
por: Skandamis, Aristeidis, et al.
Publicado: (2019)

Systematic review and meta-analysis of prognostic factors of acute exacerbation of idiopathic pulmonary fibrosis
por: Kamiya, Hiroyuki, et al.
Publicado: (2020)

Effects of Nintedanib on Quantitative Lung Fibrosis Score in Idiopathic Pulmonary Fibrosis
por: Lancaster, Lisa, et al.
Publicado: (2020)

Prognostic factors for acute exacerbation of idiopathic pulmonary fibrosis: protocol for a systematic review and meta-analysis
por: Kamiya, Hiroyuki, et al.
Publicado: (2019)

Analysis of the safety and efficacy of different plasma concentrations of pirfenidone in patients with idiopathic pulmonary fibrosis
por: Li, Hui, et al.
Publicado: (2022)

Real world experience on the effectiveness and safety of pirfenidone in patients with idiopathic pulmonary fibrosis in Taiwan
por: Chang, Cheng-Yu, et al.
Publicado: (2023)

Prognostic significance of autoantibodies for idiopathic pulmonary fibrosis: protocol for a systematic review
por: Kamiya, Hiroyuki, et al.
Publicado: (2018)

Efficacy of N-acetylcysteine on idiopathic or postinfective non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis protocol
por: Luo, Ai, et al.
Publicado: (2022)

Prognosis of acute exacerbation in idiopathic pulmonary fibrosis with pulmonary emphysema: a retrospective cohort study in Japan
por: Horio, Yukihiro, et al.
Publicado: (2022)

Longitudinal “Real-World” Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece
por: Tzouvelekis, Argyrios, et al.
Publicado: (2017)

Exploration of the unmet needs of patients diagnosed with idiopathic pulmonary fibrosis: a scoping review protocol
por: Bramhill, Carita, et al.
Publicado: (2023)

Idiopathic Pulmonary Fibrosis Registry China study (PORTRAY): protocol for a prospective, multicentre registry study
por: Xie, Bingbing, et al.
Publicado: (2020)

Corrigendum: Longitudinal “Real-World” Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece
por: Tzouvelekis, Argyrios, et al.
Publicado: (2018)

The Efficacy and Safety of Long-term Pirfenidone Therapy in Patients with Idiopathic Pulmonary Fibrosis
por: Ogawa, Kazumasa, et al.
Publicado: (2018)

Updated Evaluation of the Safety, Efficacy and Tolerability of Pirfenidone in the Treatment of Idiopathic Pulmonary Fibrosis
por: Gulati, Swati, et al.
Publicado: (2020)

Retrospective observational study of trends in hospital admissions for idiopathic pulmonary fibrosis in Spain (2004–2013) using administrative data
por: Pedraza-Serrano, Fernando, et al.
Publicado: (2017)

Ambulatory oxygen for treatment of exertional hypoxaemia in pulmonary fibrosis (PFOX trial): a randomised controlled trial
por: Holland, Anne E, et al.
Publicado: (2020)

Pirfenidone treatment of idiopathic pulmonary fibrosis
por: Gan, Ye, et al.
Publicado: (2011)

Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond
por: Aimo, Alberto, et al.
Publicado: (2022)

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis
por: Flaherty, Kevin R., et al.
Publicado: (2018)

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
por: Lancaster, Lisa H., et al.
Publicado: (2017)

A mixed-methods study of the Care Needs of individuals with idiopathic Pulmonary fibrosis and their carers—CaNoPy: a study protocol
por: Byrne, Anthony, et al.
Publicado: (2013)

Historical database cohort study addressing the clinical patterns prior to idiopathic pulmonary fibrosis (IPF) diagnosis in UK primary care
por: Thickett, David, et al.
Publicado: (2020)

Efficacy and safety of whole-lung lavage for pulmonary alveolar proteinosis: a protocol for a systematic review and meta-analysis
por: Liu, Shixu, et al.
Publicado: (2022)

Efficacy and adverse events of pirfenidone in treating idiopathic pulmonary fibrosis
por: Ren, Hui, et al.
Publicado: (2017)

Acute Exacerbation of Idiopathic Pulmonary Fibrosis With Pirfenidone and Nintedanib: A Friend or Foe
por: Kaushal, Mohit, et al.
Publicado: (2022)

Effects of the COVID-19 pandemic on the follow-up and treatment of patients with idiopathic pulmonary fibrosis: a cross-sectional, multicentre phone call survey
por: Coskun, Funda, et al.
Publicado: (2021)

The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis
por: Cottin, Vincent
Publicado: (2013)

The effects and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis: a meta-analysis and systematic review
por: Zang, Chenchen, et al.
Publicado: (2021)

Efficacy of remdesivir in patients with COVID-19: a protocol for systematic review and meta-analysis of randomised controlled trials
por: Gebrie, Desye, et al.
Publicado: (2020)

Pirfenidone for Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis
por: Aravena, Carlos, et al.
Publicado: (2015)

Efficacy and safety of GHX02 in the treatment of acute bronchitis: protocol of a phase II, double-blind, randomised placebo-controlled trial
por: Lyu, Yee Ran, et al.
Publicado: (2018)

Case Report: Pirfenidone in the Treatment of Post-COVID-19 Pulmonary Fibrosis
por: Zhou, Xianglin, et al.
Publicado: (2022)

Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis
por: Valeyre, Dominique, et al.
Publicado: (2014)

Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)
por: Richeldi, Luca, et al.
Publicado: (2023)

Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis
por: van Manen, Mirjam J.G., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_rt66ge9c6qu7f9p0gdt1hh8jb0